Latigo Biotherapeutics, Inc. (LTGO) company profile
LTGONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 5, 2026
$13.76+1.16 (+9.21%)
Close on Nov 17, 2026Market cap $912.28MP/E –Yield 0.00%
About Latigo Biotherapeutics
Pharmaceutical Preparations, SIC 2834
Latigo Biotherapeutics, Inc. is listed on Nasdaq under the ticker LTGO, in the SEC industry Pharmaceutical Preparations. It is incorporated in Delaware and its fiscal year ends on December 31. Reported financials on StockData start in fiscal 2024.
Company profile
Company
- Legal name
- Latigo Biotherapeutics, Inc.
- Headquarters
- Thousand Oaks, CA
- Address
- 1300 Rancho Conejo Blvd., Suite 305
- Phone
- (805) 716-2927
- Website
- latigobio.com
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
Stock & identifiers
- Ticker
- LTGO
- Exchange
- Nasdaq
- IPO date
- Aug 7, 2026
- Shares outstanding
- 66M, Sep 1, 2026
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 2056611
- CUSIP
- 517954103
- ISIN
- US5179541033
- FIGI
- BBG01LGT3SL3
- Share class FIGI
- BBG01LGT3SM2
- EIN
- 83-2625838
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Nima Farzan | President and CEO, Director | 114,453 |
| Neha Krishnamohan | CFO and Chief Business Officer | – |
| Neil Singla | Chief Medical Officer | – |
| Todd N. Smith | Director | – |
| Beth C. Seidenberg | Director | 4,916,374 |
| James B. Tananbaum | Director | 3,117,664 |
| Timothy P. Walbert | Director | – |
| Sara Bonstein | Director | – |
| Kevin Raidy | Director | – |
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Aug 7, 2026
- Offer price
- $18.00
- Securities offered
- 19,200,000
- Gross proceeds
- $345.60M
- Exchange
- Nasdaq
- First trading day
- Aug 7, 2026
- First-day close
- $18.25+1.4%
- Lock-up ends (est.)
- Feb 3, 2027
“The initial public offering price is $18.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 7, 2026 | IPO | Initial public offering priced (424B4 prospectus) |
| Aug 4, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?